劑泰科技－Ｐ Hisse Grafiği

Metis TechBio Co., Ltd. provides AI based nanomaterials delivery and application services. The company developed three proprietary platform technologies: AiLNP (AI Nano Delivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform), and AiTEM (AI Small Molecule Formulation Design Platform). It develops, simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads through AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives. The company was founded by Christopher Lai, Hongming Chen and Wenshou Wang on January 10, 2010 and is headquartered in Beijing, China.